Test121212121212
0 Circular
testewwwww
Test12121212121
CIRCULAR (N0.249) EYE SOLUTION CINTINING TROPICAMIDE ADDED TO THE LIST OF CONTROLLED DRGS
CIRCULAR(NO.226) PRAC recommendations on signals in respect of Fluoroquinolones for systemic and inhalation formulations
CIRCULAR(NO.222) MHRA update about Ferric Carboxymaltose (Ferinject)
CIRCULAR (N0.197)Drug safety communication about Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
CIRCULAR (No.168) FDA Safety Alert reg. Invokana, Invokamet (Canagliflozin)
CIRCULAR (NO.149)Half Yearly Report of PV (Jan-Jun 2020)
CIRCULAR(No.144)Updating of data related to QPPV,QPPV Back up and LSR
CIRCULAR (NO.142) EMA’s notification about authorized uses of the cancer medicine Yondelis
CIRCULAR (NO.141)Azithromycin review of QT prolongation in the context of COVID 19 infection
CIRCULAR (NO.112)A reminder of The Risks of Chloroquine and HydroxyChloroquine
CIRCULAR (NO.88)The use of Hydorxychloroquine Plaquenil® in the context of COVID 19
CIRCULAR (NO.84) Chloroquine & HydroxyChloroquine
CIRCULAR (NO.83)2Repoting of ICSR
CIRCULAR(NO.77)European Medicine Agency’s recommendations to restrict use of fosfomycin antibiotics
CIRCULAR(NO.76)European Medicine Agency’s notification about restrictions in use of cyproterone due to meningioma risk
CIRCULAR(NO.75) European Medicine Agency’s notification that no change is needed in use of direct oral anticoagulants
CIRCULAR(NO.69) Hydroxychloroquine
Circular(No.62) Regarding Montelukast -Strengthened Boxed Warning due to restricting use for allergic rhinitis
CIRCUALR (NO.41)Restrictions in use of Cyproterone due to meningioma risk
CIRCULAR(NO.39) Clozapine – FDA strengthens warning that untreated constipation can lead to serious bowel problems
CIRCULAR (NO.31)ISoP 2020 Meeting in Muscat
CIRCULAR(NO.26) European Medicines Agency's Safety Committee (PRAC) confirms four week limit for use of high -strength estradiol creams
CIRCULAR (NO.110) FDA warning about Gabapentin or Pregabalin
CIRCULAR (No. 96) EMA's recommendation that Xeljanz to be used with caution in patients at high risk of blood clots
CIRCULAR( No.97 )Lemtrada - EMA's recommendation for restriction of the use of Lemtrada
CIRCULAR (NO.83) ADR Reporting - Additional Link
CIRCULAR (NO.76) Support for The Annual of ISoP 2020 in Oman
